Elliot D. Rosenstein
- ASSOCIATE CLINICAL PROFESSOR Medicine, Clinical Immunology
MD, Mount Sinai School of Medicine
Elliot Rosenstein is the recently appointed Director of the Institute for Rheumatic & Autoimmune Disease at Overlook Hospital, Summit, NJ.
After graduating from Tufts University with a bachelor of sciences in biology (summa cum laude), he received his medical degree from Mount Sinai School of Medicine, where he was elected to Alpha Omega Alpha, the medical honor society. He completed his internship, residency, and chief residency in internal medicine, and fellowship in clinical and experimental rheumatology at New York University/Bellevue Medical Center. He is currently Associate Clinical Professor in the Division of Clinical Immunology at Mount Sinai and is on adjunct faculty at NYU and New Jersey Dental School.
He is a Fellow of the American College of Physicians and the American College of Rheumatology. He is a also a Member of the American Federation for Medical Research, New York Academy of Sciences, Clinical Immunology Society and American Association of Immunologists.
He has published over 60 scientific articles, monographs and chapters, including the pivotal observation connecting rheumatoid arthritis with the major pathogen in periodontal disease. His research interests also include mechanisms of autoimmunity, treatment of rheumatoid arthritis and other inflammatory diseases with novel therapeutic agents and approaches.
He is a former editor of the American College of Rheumatology Hotline.
He has been cited in New York Magazine, New Jersey Magazine and in Best Doctors in America.
He has recently completed several years as the President of the New Jersey Rheumatology Association. He has been appointed to the Board of Directors of the Arthritis Foundation-New Jersey Chapter and the Scientific Advisory Board of the Lupus Foundation of America-New Jersey Chapter.
Rheumatologist of the Year
Arthritis Foundation-New Jersey Chapter
Thomas P Infusino Lectureship
Lautenberg Center for General and Tumor Immunology
1997 - 2011
1983 - 1984
Catherine & Gilbert Miller Fellowship
Arthritis Foundation-NY Chapter
Alpha Omega Alpha
RA and periodontal disease
described the association bewteen rheumatoid arthritis and Porphyromonas gingivalis, the major pathogen in periodontal disease.
Rosenstein ED, Greenwald RA, Kushner LJ, Weissmann G. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 2004 Dec; 28(6).
Rosenstein ED, Weissmann G, Greenwald RA. Porphyromonas gingivalis, periodontitis and rheumatoid arthritis. Medical hypotheses 2009 Sep; 73(3).
Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, Zubair M, Rivera V. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford, England) 2009 Jan; 48(1).
Sen D, Rosenstein ED, Kramer N. ANCA-positive vasculitis associated with simvastatin/ezetimibe: expanding the spectrum of statin-induced autoimmunity?. International journal of rheumatic diseases 2010 Aug; 13(3).
Greenberg JD, Fisher MC, Kremer J, Chang H, Rosenstein ED, Kishimoto M, Lee S, Yazici Y, Kavanaugh A, Abramson SB. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clinical and experimental rheumatology; 27(3).
Bhangle SD, Kramer N, Rosenstein ED. Spondyloarthropathy after ampullary carcinoma resection: . Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2009 Aug; 15(5).
Rosenstein ED, Warshauer BL. Alopecia areata and autoimmunity. Journal of the American Academy of Dermatology 2010 Jun; 62(6).
Patel S, Kramer N, Rosenstein ED. Evolving connective tissue disease influenced by splenectomy: beneath the sword of Dameshek. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2010 Sep; 16(6).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Rosenstein is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Institute for Rheumatic & Autoimmune Diseases
33 Overlook Road, Suite 211
Summit, NJ 07901